Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
B. Garfield (London, United Kingdom), C. Mcfadyen (London, United Kingdom), C. Briar (London, United Kingdom), C. Mccabe (London, United Kingdom), S. Ledot (London, United Kingdom), M. Baldwin (London, United Kingdom), K. Vlachou (London, United Kingdom), S. Price (London, United Kingdom), S. Wort (London, United Kingdom), B. Patel (London, United Kingdom), L. Price (London, United Kingdom). Potential for personalised application of inhaled nitric oxide in Covid-19 pneumonia. 3325

Member's Comments

No comment yet.

Related content which might interest you: Predicting response to corticosteroid in COPD using exhaled nitric oxide Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Changes of exhaled nitric oxide during steroid treatment of childhood asthma Source: Eur Respir J 2002; 19: 1015-1019 Year: 2002 Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Clinical utility of fractional exhaled nitric oxide in severe asthma management Source: Eur Respir J, 55 (3) 1901633; 10.1183/13993003.01633-2019 Year: 2020 Exhaled nitric oxide variations during oral challenge with different NSAIDs in patients with aspirin-induced asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD Source: Breathe, 15 (4) 306; 10.1183/20734735.0268-2019 Year: 2019 The nitric oxide (NO) metabolites in monitoring and therapy of bronchial asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Exhaled nitric oxide and inhaled steroids in patients with stable asthma in primary care Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma Year: 2003 Investigation on the effectiveness of the Mostgraph and fractional exhaled nitric oxide measurement in chronic cough Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Onset of action of inhaled corticosteroids on bronchial and alveolar nitric oxide output Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 The role of exhaled nitric oxide in the evaluation of chronic cough Source: Eur Respir J 2006; 28: Suppl. 50, 794s Year: 2006 Experiences of exhaled nitric oxide measurements in diagnostics of occupational asthma Source: Eur Respir J 2001; 18: Suppl. 33, 281s Year: 2001 Bronchial nitric oxide output predicts responsiveness to inhaled steroids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 429s Year: 2004 Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Source: Eur Respir J 2002; 20: 630-634 Year: 2002 Acinar effect of inhaled steroids therapy evidenced by exhaled nitric oxide Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Features of production nitric oxide at patients with a bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 445s Year: 2006 Exhaled nitric oxide in the assessment of asthma control Source: Eur Respir J 2007; 30: Suppl. 51, 18s Year: 2007 Effect of caffeine on exhaled nitric oxide measurements in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 180s Year: 2003 Exhaled nitric oxide increases in chronic eosinophilic pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 509s Year: 2002